Arthneeti
Financial resultsMajor development· Adverse for the businessFiled on BSE ·

Dr. Reddy's approves Q1 FY27 results; Deloitte Haskins & Sells named 20-F auditor

Dr Reddys Laboratories · Pharmaceuticals & Biotechnology

Arthneeti Research DeskPublished 1 min read

Key highlights

  • Board approved unaudited consolidated results for quarter ended June 30, 2026 under IFRS and Ind AS, and standalone results under Ind AS.
  • Board approved Deloitte Haskins & Sells, LLP as Independent Registered Public Accounting Firm for the Form 20-F annual audit and Form 6-K interim reviews.
  • Board approved appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026.

Why it's rated major development: the year-on-year change is 69% (20% or more for adverse news)

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Unaudited Financial Results For The Quarter Ended June 30, 2026

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Other financial results filings this fortnight

All financial results filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.